Clinical Trial Results:
A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazide 32/12.5 mg and 32/25 mg in Comparison with Candesartan Cilexetil 32 mg Alone in Patients with Inadequate Blood Pressure Control on Monotherapy with Candesartan Cilexetil 32 mg
Summary
|
|
EudraCT number |
2005-005718-19 |
Trial protocol |
LT EE DE SE NL DK GB |
Global completion date |
17 Aug 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
17 Jul 2016
|
First version publication date |
17 Jul 2016
|
Other versions |
|
Summary report(s) |
CSR-D2456C00001 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.